(Q33372925)

26 July 2017

title

Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy (English)

1 reference

Markus Peck-Radosavljevic

26 July 2017

1 reference

1 reference

1 reference

1 reference

8

object named as

Markus Peck-Radosavljevic

0 references

author name string

Monika Homoncik

1

1 reference

26 July 2017

Wolfgang Sieghart

2

1 reference

26 July 2017

Elisabeth Formann

3

1 reference

26 July 2017

Monika Schmid

4

1 reference

26 July 2017

Peter Ferenci

5

1 reference

26 July 2017

Alfred Gangl

6

1 reference

26 July 2017

Bernd Jilma

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

The American Journal of Gastroenterology

26 July 2017

published in

1 reference

26 July 2017

volume

101

1 reference

26 July 2017

issue

10

1 reference

26 July 2017

page(s)

2275-2282

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Side effects of therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00774.X

10.1111/J.1572-0241.2006.00774.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference